) The Greenville, South Carolina CCOP has long-term objectives that include: (1) Increasing the availability of NCI-supported clinical trials to the substantial minority and underserved populations of this area. (2) Expanding the involvement of primary care providers and other specialists in cancer prevention and cancer control clinical trials. (3) Translating the latest research findings to residents and practitioners of the service area. (4) Establishing tumor registries in rural hospitals to enhance recruitment and access to clinical research. First, the CCOP will create new alliances among other local oncology and primary care practitioners by contacting physicians with information about the use of nationally sponsored treatment and cancer control trials and funding available for data management. This cooperative effort will allow the CCOP to establish long-term relationships with local physicians and their patients, a concept essential to the recruitment of the minority population. It is hoped that formalizing partnerships with our local VA Hospital(s) will allow us access to a stable population among whom cancer prevention has been legislated. In addition, research nurses will be able to implement regular screening programs for potential participants and survey pertinent medical r e c o rds from local surgeons and primary care physicians. Second, chemoprevention and cancer control trials for colorectal, gynecologic, and head and neck cancers will be aggressively marketed to physicians who have not been involved in research in the past. The addition of the MD Anderson Cancer Center and the GOG as research bases will allow recruitment to previously unavailable cancer control studies. The CCOP Executive Board will be expanded as a forum for problem solving and obtaining input from the community. The mailing list of the Greenville CCOP and the dissemination of our quarterly newsletter will be expanded to include physicians in outlying areas. Our goal is to further broadcast the concept and importance of cancer prevention whether or not it translates into actual patient accrual. Third, the availability of these trials to the community will be a mechanism utilized by the CCOP to promote overall cancer education and awareness. Through semi-annual lectures on specific disease sites delivered by speakers who are associated with cooperative group research, we will translate basic science to clinical research emphasizing existing protocols. These scientific meetings will coincide with CCOP general meetings to increase participation. Fourth, the establishment of tumor registries in rural areas will allow for more consistent and updated information as it relates to cancer incidence in our catchment area. This will be accomplished by meeting with medical records personnel and local pathologists to educate them regarding the importance of tracking cancer diagnoses. This cooperative effort will better equip the CCOP to pinpoint areas where cancer prevention and education is necessary and where screenings should occur.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA067663-05
Application #
2895290
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Program Officer
Parnes, Howard L
Project Start
1995-09-25
Project End
2001-05-31
Budget Start
1999-06-10
Budget End
2000-05-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Oncology & Hematology Associates of SC
Department
Type
DUNS #
City
Greenville
State
SC
Country
United States
Zip Code
29605
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 95 publications